Linked Life Data

21342034

Source:http://linkedlifedata.com/resource/pubmed/id/21342034

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2011-2-23
pubmed:abstractText
Evaluation of: Kaufmann M, Maass N, Costa SD et al. First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial. Eur. J. Cancer 46, 3184-3191 (2010). Breast cancer is the most frequent malignant disease in women. Although fewer than 10% of patients show metastatic disease at diagnosis, approximately one in every five patients will relapse. Great biologic heterogeneity in breast cancer is well known due to the implementation of newer molecular technologies. This knowledge has led to a better development and selection of new therapies. Regimens based on taxanes and anthracyclines are the classical treatments accepted as first-line therapy. Capecitabine is an orally administered systemic prodrug of 5´-deoxy-5-fluorouridine, which is converted to 5-fluorouracil with a favorable but different toxicity profile to other cytotoxic drugs. However, a considerable proportion of patients need to suspend or reduce the dose of capecitabine when it is administrated at the registered dose of 1250 mg/m(2) twice daily 14 days every 21 owing to adverse events. In this study, Kaufmann et al. show the activity and safety of capecitabina at a lower dose (1000 mg/m(2) twice daily) at first-line therapy in HER2-negative metastatic breast cancer.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:status
PubMed-not-MEDLINE
pubmed:month
Feb
pubmed:issn
1744-8328
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
165-8
pubmed:year
2011
pubmed:articleTitle
Safety and efficacy of moderate-dose capecitabine as first-line therapy in metastatic breast cancer.
pubmed:affiliation
Medical Oncology Service, Hospital Universitario 12 de Octubre, Avda CÃ3rdoba Km 5, 4 Madrid 28041, Spain. hcortes.hdoc@salud.madrid.org
pubmed:publicationType
Journal Article, Comment